CCM
AEON icon

CAAS Capital Management’s AEON Biopharma AEON Stock Holding History

CAAS Capital Management’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-164
Closed -$120K – 676
2023
Q1 		$120K Buy
+164
New +$119K 0.01% 610

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CAAS Capital Management's AEON Position: Q2 2023 in Review

CAAS Capital Management sold out of AEON Biopharma (AEON) in Q2 2023, closing a stake of 164 shares — an estimated $120K sold.

CAAS Capital Management first reported a position in AEON in Q1 2023 and held it in 1 quarter. The position peaked at $120K in Q1 2023. 17 funds tracked by Wall St. Rank hold AEON as of Q2 2023.

  • CAAS Capital Management reported no remaining AEON Biopharma position as of Q2 2023 after selling out during the quarter.
  • CAAS Capital Management sold 164 AEON Biopharma shares in Q2 2023, an estimated $120K.
  • CAAS Capital Management first reported a position in AEON Biopharma in Q1 2023 and held it in 1 quarter.
  • CAAS Capital Management's AEON Biopharma position peaked at $120K in Q1 2023.
  • 17 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2023.

Based on CAAS Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.